Cambridge Nutritional Sciences PLC
LSE:CNSL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (0.3), the stock would be worth GBX4.41 (121% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.2 | GBX2 |
0%
|
| 3-Year Average | 0.3 | GBX4.41 |
+121%
|
| 5-Year Average | 0.3 | GBX4.41 |
+121%
|
| Industry Average | 0 | GBX0.08 |
-96%
|
| Country Average | 0 | GBX0.05 |
-97%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
GBX1.2m
|
/ |
Oct 2025
£8.1m
|
= |
|
|
GBX1.2m
|
/ |
Mar 2026
£7.6m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Cambridge Nutritional Sciences PLC
LSE:CNSL
|
4.8m GBP | 0.2 | 3.5 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.9T JPY | 10.2 | 39.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.1B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
29B CHF | 3.7 | 36.4 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
92B DKK | 4 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.7B USD | 2.9 | 30.9 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.2B GBP | 2.9 | 31.8 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
39.1B CNY | 8.1 | 23.7 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
905.8B JPY | 6.6 | 51.2 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | 99.2 | -37.8 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 2 | -15.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 3 279.7 |
Other Multiples
Cambridge Nutritional Sciences PLC
Glance View
Cambridge Nutritional Sciences Plc is a holding company, which engages in the manufacture, development, and distribution of medical diagnostics products. The firm develops, manufactures and markets diagnostic products associated with food sensitivity and gut health. The firm serves healthcare professionals and the consumer directly with a focus on health and nutrition products.
